BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals Announces Board Chair Transition

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsCompany update

Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery

Related news

LEGNLegend Biotech Corporation2026-07-27 10:00 EST

Legend Biotech Announces CEO Transition

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

MGNXMacroGenics2026-07-02 13:25 EST

MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals

RVMDRevolution Medicines2026-06-22 12:00 EST

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

ZNTLZentalis2026-06-01 21:00 EST

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

IDYAIDEAYA Biosciences2026-06-17 10:00 EST

IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors

ENTAEnanta Pharmaceuticals2026-05-28 11:00 EST

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

View all latest news

PMV Pharmaceuticals

Mutant p53 Precision Oncology PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53. Rezatapopt Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function. Ovarian Cancer Lead Indication The PYNNACLE...

Recent company news

PMVPPMV Pharmaceuticals2026-05-12 12:00 EST

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-04-22 12:00 EST

PMV Pharmaceuticals Announces Board Chair Transition

PMVPPMV Pharmaceuticals2026-03-06 13:00 EST

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights

PMVPPMV Pharmaceuticals2026-02-26 13:00 EST

New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors

PMVPPMV Pharmaceuticals2025-11-12 13:01 EST

PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights

Stock data

Close
1.18 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States